943d A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SCW. Sandborn, P. J. Rutgeerts, Jewel Johanns et al.|Gastroenterology|2012Cited by 27
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-MaintenanceWilliam J. Sandborn, Paul Rutgeerts, Brian Feagan et al.|The American Journal of Gastroenterology|2012Cited by 1